Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A Expertise NORFOLK, Va., January 7, 2026 – ReAlta Life...
Read MorePegtarazimod demonstrates significant clinical improvement and reduction in inflammatory markers in patients with lower gastrointestinal acute GvHD NORFOLK, Va.–ReAlta Life...
Read MoreReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components...
Read MoreNORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory...
Read MoreReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory...
Read MoreAccomplished biopharma executive brings nearly 25 years of experience in business development, capital formation, and enterprise strategy to this role...
Read MoreStudy shows pegtarazimod reduces microglial activation associated with pathogenic neuroinflammation in hypoxic ischemic encephalopathy, as well as neurodegenerative diseases such...
Read MoreNORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the...
Read MoreData confirm elevated inflammatory biomarkers in newborns with Hypoxic Ischemic Encephalopathy (HIE) and demonstrate a predictable pharmacokinetic profile for RLS-0071...
Read More